FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.
What happened
FDA inspected the Miami clinical site from January 11 to January 30, 2023, under its Bioresearch Monitoring Program. FDA found subjects enrolled without protocol-required eligibility documentation, a subject randomized without required e-Diary entries, and protocol-required safety imaging visits missed. The investigator's February 17, 2023 response was inadequate because it lacked supporting documentation and sufficient corrective-action details.
What FDA found
Failed to ensure the clinical investigation was conducted according to the investigational plan.
21 CFR 312.60Randomized subjects without documented surgical diagnosis within 10 years before screening, as the protocol required, and gave them multiple doses of investigational drug.
21 CFR 312.60Randomized a subject without the protocol-required electronic diary documentation.
21 CFR 312.60Did not perform protocol-required safety imaging at specified study visits for three subjects.
21 CFR 312.60
What FDA wants
Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. Include sufficient details about corrective actions and any planned or completed training.
Who should pay attention
- clinical trial sponsors and CROs
- research sites and investigators
- IRBs overseeing drug trials
This is a summary. Read the original letter on fda.gov.